Does ITI Actually Work in Hemophilia B – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Shaoyu Yin et al, adding:
“Immune tolerance induction (ITI) in hemophilia B: does it actually work?
This systematic review makes one thing clear: ITI in hemophilia B is unpredictable and risky.
What the data show:
Across 125 patients:
- Success rates vary wildly (from 12.8 pecent to 100 percent)
- Time to tolerance: approximately 1 to 19 months
- Multiple attempts often needed
The real challenge: safety
Adverse events are not rare, they’re defining:
- Allergic reactions: from 0 to 100 percent
- Nephrotic syndrome: from 0 to 33 percent
These complications are far more common than in hemophilia A.
This is the key issue:
- No standardized definition of ‘success.’
- No uniform ITI protocol
- Small, heterogeneous cohorts
We’re comparing apples to oranges across studies.
Clinical insight
- ITI can still work, even after failure or allergic reactions
- But nephrotic syndrome is a major red flag (often treatment-limiting)
- Immunosuppression is widely used but doesn’t eliminate risk
Big picture
Unlike hemophilia A, where ITI is established: Hemophilia B remains a high-risk, low-predictability space
And until we standardize protocols: We’re optimizing therapy without a common playbook.”
Title: Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review
Authors: Shaoyu Yin, Jiahong Wu, Wen Yang, Hongli Mu, Yuexing Peng, Haoran Lu, Rong Li, Hui Bi, Zeping Zhou
Read the Full Article on Research and Practice in Thrombosis and Haemostasis
See more in the gallery.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic